Skip to main content
. 2014 Apr 17;14:50. doi: 10.1186/1471-2318-14-50

Table 3.

Immune phenotypes as a function of age, sex, frailty and nutritional status

Immune phenotype
Age Correlation + (r) n = 262
Sex Median (IQR ) n = 262 ++
Clinical Frailty Scale Median (IQR) n = 262 +++
Nutritional Status Median (IQR) n = 261 a+++
    Female n = 213 Male n = 49 4 n = 64 5 n = 62 6 n = 94 7 or 8 n = 42 Normal n = 127 At risk n = 121 Mal-nourished n = 13
CD8+
CD8 + %
0.05
17.1
17.4
18.6
17.6
16.3
16.3
17.4
17.1
17.1
(11.8-24.2)
(12.8-22.2)
(13.7-23.8)
(12.3-21.9)
(11.7-24.1)
(9.7-26.8)
(12.2-23.8)
(11.7-24.2)
(11.2-20.9)
Naïve CD8 + %
−0.13*
0.9
0.8
0.9
0.8
1.0
1.2
0.9
1.0
0.7
(0.5-1.5)
(0.4-1.2)
(0.5-1.4)
(0.5-1.4)
(0.5-1.4)
(0.5-2.1)
(0.5-1.4)
(0.58-1.6)
(0.3-1.2)
Central memory CD8 + %
−0.03
0.6
0.5
0.5
0.5
0.6
0.7
0.5
0.7
0.5
(0.3-1.0)
(0.3-0.8)
(0.3-0.9)
(0.3-0.9)
(0.3-1.0)
(0.3-1.5)
(0.3-0.9)
(0.3-1.1)
(0.4-0.9)
Effector memory CD8 + %
−0.04
6.1
7.1
6.7
6.3
6.3
5.7
6.5
6.0
6.0
(3.8-9.5)
(4.5-9.7)
(4.1-9.9)
(4.1-8.7)
(3.7-10.0)
(4.0-8.6)
(3.8-9.9)
(3.9-8.8)
(4.0-10.9)
Terminally differentiated CD8 + %
0.08
7.8
5.9
8.9
7.6
6.9
6.1
8.1
7.2
5.8
(3.6-12.6)
(3.3-12.5)
(4.2-13.3)
(3.7-12.8)
(3.4-11.0)
(2.4-12.9)
(3.5-12.7)
(3.6-12.5)
(3.1-10.9)
Senescent CD8 + %
0.04
5.1
5.7
6.2
5.0
5.1
4.9
5.1
5.2
5.6
(2.3-8.9)
(2.0-11.3)
(2.8-11.4)
(2.3-9.3)
(2.2-7.9)
(0.8-10.0)
(2.2-10.0)
(2.3-8.6)
(1.2-9.5)
CD4+
CD4 + %
−0.06
46.1*
42.1*
44.9
45.8
46.4
43.1
46.1
45.8
42.0
(39.1-53.8)
(34.7-49.1)
(38.6-53.6)
(37.1-52.6)
(40.4-53.1)
(32.4-52.7)
(38.7-52.6)
(36.1-53.5)
(35.9-44.9)
Naïve CD4 + %
0.05
10.1*
7.1*
10.5
9.2
9.3
7.2
10.4*
8.7*
5.9*
(5.4-14.6)
(4.6-11.5)
(5.4-18.0)
(5.3-14.7)
(5.4-13.1)
(4.0-12.2)
(5.4-16.1)
(4.8-12.5)
(3.4-9.9)
Central memory CD4 + %
−0.08
12.8
11.7
12.5
12.0
13.3
12.8
12.5
13.1
10.7
(9.6-16.4)
(8.7-14.6)
(9.0-15.4)
(8.4-16.2)
(10.7-18.2)
(8.7-15.8)
(9.2-16.2)
(9.0-17.2)
(9.3-13.3)
Effector memory CD4 + %
0.13*
18.9
18.2
19.3
18.1
19.2
17.0
18.6
19.0
18.5
(14.6-23.0)
(12.9-21.4)
(13.6-21.8)
(12.7-21.9)
(15.2-24.2)
(13.5-22.4)
(13.5-21.8)
(14.6-22.8)
(12.8-26.6)
Terminally differentiated CD4 + %
0.05
1.9*
1.4*
1.9
1.8
1.6
1.8
1.9
1.6
1.4
(1.1-2.9)
(0.6-2.5)
(1.1-3.3)
(1.1-2.6)
(1.1-2.7)
(0.8-2.7)
(1.1-2.9)
(1.0-2.8)
(0.9-2.0)
Senescent CD4 + %
0.11
1.4
1.3
1.5
1.4
1.4
1.2
1.4
1.3
2.0
(0.3-3.5)
(0.2-2.9)
(0.3-4.2)
(0.1-3.1)
(0.3-3.6)
(0.2-2.9)
(0.16-3.4)
(0.27-3.2)
(0.34-4.4)
T-reg
T-reg%
0.08
1.8
1.6
2.5 **
2.0**
1.6**
1.0**
2.2**
1.6**
1.0**
(1.2-2.6)
(0.9-2.6)
(1.8-2.9)
(1.3-2.6)
(1.1-2.3)
(0.8-1.5)
(1.5-2.9)
(1.1-2.3)
(0.8-1.2)
Ratio
 
CD4 + : CD 8 + ratio
−0.06
2.6
2.5
2.5
2.4
2.7
2.6
2.6
2.6
2.3
(1.7-4.5)
(1.6-3.5)
(1.6-3.8)
(1.8-4.1)
(1.9-4.5)
(1.4-5.0)
(1.7-4.1)
(1.6-4.5)
(1.8-3.3)
NK
Mature NK cell%
−0.05
12
12.6
12.0
11.3
12.3
12.7
12.3
11.6
14.7
(8.0-16.6)
(7.1-17)
(8.3-6.3)
(7.1-15.2)
(7.3-16.7)
(8.5-17.2)
(8.7-16.0)
(6.8-16.5)
(7.9-18.4)
Senescent NK cell%
−0.10
1.4
1.5
1.0**
1.1**
1.7**
2.0**
1.3*
1.6*
1.4*
(0.9-2.2)
(1.0-2.4)
(0.7-1.9)
(0.7-1.9)
(1.0-2.7)
(1.3-2.7)
(0.74-2.1)
(1.0-2.7)
(1.1-2.3)
Immature NK cell% 0.03 0.2
0.3
0.2
0.21
0.3
0.3
0.2
0.2
0.2
(0.1-0.4) (0.1-0.5) (0.1-0.4) (0.1-0.3) (0.2-0.4) (0.2-0.4) (0.2-0.4) (0.1-0.4) (0.13-0.45)

*p ≤ 0.05.

**p ≤ 0.001.

aOne patient excluded as nutritional status unknown.

+Spearman’s rank test of significance used.

++Mann–Whitney U test of significance used.

+++Kruskal-Wallis test of significance used.